Connect with us

Health

Cleveland Clinic: First Patient to Receive Breast Cancer Vaccine Shares Health Journey

Published

on

The vaccine targets a lactation protein called α-lactalbumin, which is no longer found after lactation in normal, aging tissues but is present in most triple-negative breast cancers. If breast cancer develops, the vaccine is designed to prompt the immune system to attack the tumor and keep it from growing. (Courtesy: Cleveland Clinic)

#USA, April 17, 2023 – During a typical day at work, Jennifer Davis received an unexpected call that changed her life. A nurse on the other end of the line delivered the news Jennifer had triple-negative breast cancer. The mother of three recalls feeling terrified. She didn’t know how she was going to tell her family. After receiving the diagnosis, Jennifer knew she wanted to take advantage of every treatment option available. Through her driven search for answers, she became the first person to participate in a novel study at Cleveland Clinic for a vaccine that aims to eventually prevent triple-negative breast cancer.

“When I found out I was the first person to receive the vaccine, I was excited. I was thrilled. The trial has given me a lot of hope,” says Jennifer, a registered nurse from Lisbon, Ohio.  

Jennifer’s health journey started in February 2018 when she felt a lump in her breast. She went to a local hospital for follow-up, and her first biopsy showed no evidence of cancer. Months went by, and Jennifer says the lump grew. She listened to her body and continued to get it checked. Jennifer eventually received another biopsy after doctors detected abnormalities during an ultrasound. Her diagnosis was confirmed about one week later, and she sought a second opinion for her treatment.  

“I knew I wanted to go to Cleveland Clinic, so I had my first appointment there shortly after. I met my entire care team within my first few appointments and had a complete treatment plan. I was very happy with my team and was anxious to get started,” says Jennifer.  

As part of the plan, she underwent multiple rounds of chemotherapy and radiation. She also had a double mastectomy performed by breast surgeon Zahraa AlHilli, MD.  

“After the double mastectomy, I was adamant while in recovery about wanting to know what they found and whether the cancer had spread. Dr. AlHilli was able to get clear margins, and there were no signs the cancer had spread anywhere else,” says Jennifer.  

After undergoing treatment, it was during her follow-up appointments with breast medical oncologist Megan Kruse, MD, she learned about the breast cancer vaccine clinical trial.  

The vaccine is based on pre-clinical research led by the late Vincent Tuohy, PhD, who was the Mort and Iris November Distinguished Chair in Innovative Breast Cancer Research at Cleveland Clinic’s Lerner Research Institute. The vaccine targets a lactation protein called α-lactalbumin, which is no longer found after lactation in normal, aging tissues but is present in most triple-negative breast cancers. If breast cancer develops, the vaccine is designed to prompt the immune system to attack the tumor and keep it from growing.  

Research nurse coordinator Donna Lach administers the third dose of the breast cancer vaccine to Jennifer. (Courtesy: Cleveland Clinic)

“Triple-negative breast cancer is the form of the disease for which we have the least effective treatments,” said G. Thomas Budd, MD, breast medical oncologist and principal investigator for the breast cancer vaccine trial. “Long term, we are hoping this can be a true preventive vaccine that would be administered to cancer-free individuals to prevent them from developing this highly aggressive disease.”  

Jennifer is involved in phase 1a of the study, which includes patients who completed treatment for early-stage, triple-negative breast cancer within the past three years and are currently tumor-free but at high risk for recurrence.  

“There is no medication I take to make sure there’s not a recurrence,” says Jennifer. “With every ache and pain, your mind goes to the worst-case scenario. So, I was very excited when I heard about the vaccine.”  

In October 2021, Jennifer became the first patient to enroll in the trial and receive the first dose of the vaccine. “I didn’t think twice about getting the vaccine and haven’t looked back since.”  

Dr. Kruse says, “For a long time with triple-negative breast cancer, the overarching theme patients talked about is how they’re going through all this treatment but still feeling like they’re destined to have the cancer return. I think having the hope of this vaccine study where we can potentially turn that around and have some optimism as we approach the future for these patients is the best part.”  

Over the course of the study, Jennifer and other participants received three doses of the vaccine. The vaccinations were each given two weeks apart, and the participants were closely monitored for side effects and immune response. She received her last dose in November 2021 and has not noted any major side effects.  

“My husband went with me for the first vaccine. Then my mom went with me for the second and third,” says Jennifer. “I don’t know if I ever went to an appointment at Cleveland Clinic by myself, and that support has meant a lot to me.”  

Jennifer is hopeful about the vaccine trial and encourages others to stay positive amid the ongoing research. (Courtesy: Cleveland Clinic)

In February 2023, Cleveland Clinic researchers launched the next step in their study of the vaccine. The phase 1b clinical trial, conducted in partnership with Anixa Biosciences, Inc., focuses on individuals who are cancer-free, at high risk for developing breast cancer and have decided to voluntarily undergo a prophylactic mastectomy to lower their risk.  

Meanwhile, Jennifer, now 46 years old, continues to follow up with Dr. Kruse as she nears her fifth year of being in remission. Although it will take years to fully understand the vaccine’s effectiveness, she’s eager for what’s to come and hopes her story can help others diagnosed with breast cancer.  

“Even though you’re going to have days where you’re not positive, where you feel terrible – keep moving forward. If the vaccine works the way they want, it could prevent triple-negative breast cancer one day,” says Jennifer.  

Editor’s note: Dr. Tuohy was inventor of the technology, which Cleveland Clinic exclusively licensed to Anixa Biosciences. He was entitled to a portion of the commercialization revenues received by Cleveland Clinic and also held equity in the company.

Related Institutes: Lerner Research InstituteCleveland Clinic Cancer Center

Continue Reading

Bahamas News

More Bahamians Accessing HIV, STI Care Through NHI

Published

on

NASSAU, Bahamas — More Bahamians are accessing HIV and sexually transmitted infection-related healthcare through National Health Insurance, a trend the NHI Authority says should be viewed positively.

NHIA stressed in an August 6 statement that its 2025 figures measure healthcare utilisation, not newly diagnosed infections. They include beneficiaries screened, treated, monitored or receiving follow-up care, including people diagnosed previously.

“Increased utilisation of these services should be viewed as a positive development,” NHIA said.

The Authority pointed to “greater enrolment and use of NHI, improved access to screening and testing, continued treatment and monitoring of existing conditions, and increased willingness to seek medical care.”

The development comes amid a mixed three-year HIV picture. New diagnoses rose from 130 in 2023 to 156 in 2024, before declining to 142 in 2025.

NHIA said increased utilisation demonstrates that more beneficiaries are accessing needed healthcare and actively managing their health, reinforcing the importance of screening, early diagnosis and continued treatment.

Continue Reading

Health

47,459 MEASLES CASES, 44 DEATHS ACROSS AMERICAS  

Published

on

WASHINGTON, D.C. — The Americas has recorded 47,459 confirmed measles cases and 44 deaths in 2026, the region’s highest case count in 22 years, prompting the Pan American Health Organization (PAHO) to urge stronger vaccination, surveillance and rapid outbreak response.

As of July 18, cases were already more than triple the 15,011 recorded during all of 2025. Guatemala, Mexico, the United States and Peru account for 95% of confirmed cases. Guatemala leads with 30,371 cases and 26 deaths, followed by Mexico with 12,255 cases and 17 deaths.

PAHO classifies the regional public health risk as very high, citing active outbreaks, immunity gaps, international travel and populations with inadequate vaccination coverage.

The organization says prevention starts with vaccination. Countries are being urged to achieve and maintain at least 95% coverage with two doses of measles-containing vaccine, particularly protecting children and under-vaccinated communities.

Measles spreads through the air when an infected person breathes, coughs or sneezes. Symptoms can include fever, cough, runny nose, red eyes and a rash.

PAHO is urging health authorities to detect suspected cases early and respond rapidly to stop transmission. Unvaccinated and under-vaccinated people, young children and communities with limited healthcare access face increased risk of severe illness and death.

Continue Reading

Caribbean News

From Pathways to Investment: Tackling the US $6 Billion Food Challenge for the Caribbean

Published

on

By Kenroy Roach

The Caribbean’s food systems challenge is fast evolving into a broader development challenge.

Despite decades of policy attention and investment, the region remains one of the most food import-dependent in the world, spending over US$6 billion annually. At the same time, countries continue to grapple with food insecurity, high rates of diet-related non-communicable diseases, climate vulnerability, and exposure to external shocks that can disrupt supply chains and drive up food prices almost overnight.

For Small Island Developing States (SIDS), food security has shifted from an agriculture focus alone, it’s about economic resilience, health, climate resilience and sustainable growth.

Recognizing this reality, Caribbean governments have elevated food systems transformation as a regional priority through the CARICOM 25 x 25 Plus Five Agenda, which seeks to reduce food import dependence while strengthening domestic production, regional trade, and resilience. Across Barbados and the Eastern Caribbean, governments have also developed National Food Systems Pathways that identify the investments, partnerships, and policy reforms needed to transform food systems and accelerate progress toward the Sustainable Development Goals (SDGs).

Yet one challenge has remained persistent: financing.

In the face of high levels of public debt and limited fiscal space, while public investment remains critical, Caribbean governments simply cannot shoulder the financing burden alone. Transforming food systems at scale requires mobilizing far greater private capital, alongside development finance and public resources.

This was the rationale behind the recent convened in Barbados.

The Forum brought together governments, investors, international financial institutions, private sector leaders, regional organizations, and the United Nations around a simple proposition: food systems should be viewed not only as a development priority, but also as an investable asset class.

A distinguishing feature of the innovative gathering was its focus on attracting private investment—particularly private equity, impact investment, and blended finance solutions capable of supporting businesses and infrastructure across food value chains. By helping enterprises access growth capital and connecting investors with scalable opportunities, the initiative sought to unlock financing that complements public investment rather than adding to already constrained public balance sheets.

A key outcome was the launch of a regional Deal Book comprising approximately US$320 million in investment opportunities across seven countries, spanning agriculture, fisheries, agro-processing, logistics, and strategic food systems infrastructure. The Deal Book created a practical bridge between capital seeking opportunities and opportunities seeking capital, while enabling direct engagement between governments, enterprises, and investors.

The results were encouraging.

Across four sector-focused deal rooms, participants explored investment-ready and near-investment-ready opportunities and discussed blended finance private equity, risk-sharing, and partnerships to advance projects toward implementation.

The Forum highlighted a shift in perspective: food systems are now seen as strategic drivers of economic diversification, resilience, competitiveness, and growth. Investments across production, processing, logistics, and distribution can strengthen regional supply chains, create new businesses, generate jobs, and reduce vulnerability to external shocks.

For the United Nations, this experience reinforced an important lesson.

Transforming food systems requires more than the technical expertise of individual agencies. It requires integrated solutions that connect agriculture, nutrition, health, climate resilience, trade, private sector development, and financing.

This is where the Resident Coordinator System plays a critical role.

Across Barbados and the Eastern Caribbean, the Resident Coordinator Office has united UN system capabilities around a common food systems agenda. Working with FAO, WFP, the UN Food Systems Coordination Hub, and other partners, the RCO has helped align policy support, technical expertise, partnerships, and financing with nationally identified priorities.

The Forum demonstrated this integrated approach by convening governments, investors, development finance institutions, private sector actors, and UN agencies around a common objective. It showcased the UN’s comparative advantage as a trusted broker capable of connecting development priorities with investment opportunities.

The Forum’s success will be measured not by dialogue generated, but by investments mobilized, businesses expanded, and progress made toward resilient, competitive Caribbean food systems across the Caribbean.

Its most important outcome may therefore be what comes next.

The work starts now.

Kenroy Roach is Head of the UN Resident Coordinator Office for Barbados and the Eastern Caribbean

Continue Reading

FIND US ON FACEBOOK

TRENDING